Corrigendum to ‘Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review [European Journal of Cancer 184 (2023) 83–105]

The authors regret that there is a spelling error in the acknowledgements of the original article. The correct name should appear as Lazarakis, not Lazarakos. The full and correct acknowledgements statement is provided here: The authors would like to acknowledge Smaro Lazarakis, Peter MacCallum Cancer Centre/Royal Melbourne Hospital Librarian, for her assistance with designing the search strategy for this review. The authors would like to apologise for any inconvenience caused. Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic reviewEuropean Journal of CancerVol. 184PreviewImmune checkpoint inhibitors (ICI) and targeted therapies (TT) have significantly improved disease control and survival in people with stage III and IV cutaneous melanoma. Understanding the impact of therapy on health-related quality of life (HRQL) is vital for treatment decision-making and determining targets for supportive care intervention. We conducted a mixed-methods systematic review to synthesise the impact of ICIs and TT on all domains of HRQL in these populations. Full-Text PDF